Skip to main content

Table 3 The co-occurred mutations of BRAFV600E and BRAFnon-V600E cohort using univariate and multivariate logistics regression analysis

From: BRAFnon-V600E more frequently co-occurs with IDH1/2 mutations in adult patients with gliomas than in patients harboring BRAFV600E but without a survival advantage

Gene

BRAFV600E

(n = 27)

BRAFnon-V600E

(n = 25)

Univariate analysis

Multivariate analysis

Number

%

Number

%

Odds Ratio

95% Confidence Interval

P Value

Odds Ratio

95% Confidence Interval

P Value

KRAS

0

0.00

1

4.00

1,817,409,198

0.000-

1.000

   

HRAS

0

0.00

1

4.00

1,817,409,198

0.000-

1.000

   

RAF1

0

0.00

2

8.00

1,896,426,989

0.000-

0.999

   

MAP 3 K1

1

3.70

6

24.00

8.211

0.911–73.959

0.060

   

MAP 2 K1

0

0.00

2

8.00

1,896,426,989

0.000-

0.999

   

MAP 2 K2

0

0.00

4

16.00

2,077,039,084

0.000-

0.999

   

MAP 2 K4

0

0.00

2

8.00

1,896,426,989

0.000-

0.999

   

TP53

2

7.41

14

56.00

15.909

3.078–82.224

0.001

12.186

1.251–118.721

0.031

MDM2

1

3.70

3

12.00

3.545

0.344–36.561

0.298

   

MDM4

0

0.00

4

16.00

2,077,039,084

0.000-

0.999

   

CDKN2A

0

0.00

3

12.00

1,982,628,216

0.000-

0.999

   

CDKN2B

0

0.00

1

4.00

1,817,409,198

0.000-

1.000

   

IDH1/2

1

3.70

9

36.00

14.625

1.690–126.537

0.015

5.498

0.512–59.020

0.159

ATRX

2

7.41

8

32.00

5.882

1.110–31.170

0.037

0.665

0.048–9.188

0.761